

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Investor News

NeuroSearch announces the date for its third quarter 2008 interim report and related telephone conference

NeuroSearch's interim report for the third quarter 2008 will be on the agenda of a board meeting scheduled for 17 November 2008 and be released immediately hereafter.

On the same day, a telephone conference will be held at 3 pm Copenhagen time (2 pm London time, 9 am New York time). Flemming Pedersen, CEO, Anita Milland, Vice President, CFO and Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications, will present the interim report and answer questions. The telephone conference will be conducted in English and the telephone number is +44 (0)20 7162 0077. The corresponding PowerPoint presentation will be available at www.neurosearch.com after the release of the report.

Contact person:

Hanne Leth Hillman Vice President, Director of IR & Corporate Communications, telephone: +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq OMX Copenhagen. The company's core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial share of its activities is partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with, among others, Abbott and Astellas. NeuroSearch's drug pipeline comprises 14 clinical (Phase I-III) development programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity and in Type 2 diabetes (Phase III in preparation), NS2359 for depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894 for ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 for schizophrenia (Phase I) in partnership with Astellas, ACR325 for Parkinson's disease (Phase II in preparation) and bipolar disorder (Phase II in preparation), ABT-107 and ABT-560 for the treatment of various CNS disorders – both (Phase I) in collaboration with Abbott, NSD-644 for pain (Phase I) in partnership with GSK, ACR343 for Parkinson's disease (Phase I) and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.